HC Wainwright Reiterates Buy Rating for Halozyme Therapeutics (NASDAQ:HALO)

by · The Cerbat Gem

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $65.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 9.83% from the company’s current price.

Several other equities analysts have also commented on the stock. TD Cowen raised their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Benchmark restated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Wells Fargo & Company raised their target price on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. Piper Sandler cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the stock from $48.00 to $51.00 in a report on Friday, June 7th. Finally, The Goldman Sachs Group raised their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $60.00.

Check Out Our Latest Analysis on Halozyme Therapeutics

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $59.18 on Friday. Halozyme Therapeutics has a 12-month low of $32.83 and a 12-month high of $65.53. The company’s 50 day moving average price is $58.96 and its two-hundred day moving average price is $50.35. The firm has a market cap of $7.53 billion, a PE ratio of 24.45, a PEG ratio of 0.56 and a beta of 1.27. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. The firm had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The company’s revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the company earned $0.68 EPS. Equities research analysts predict that Halozyme Therapeutics will post 3.71 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the transaction, the chief financial officer now owns 15,480 shares in the company, valued at $834,836.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Nicole Labrosse sold 5,000 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the sale, the chief financial officer now directly owns 15,480 shares in the company, valued at $834,836.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the transaction, the director now directly owns 69,874 shares in the company, valued at $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 84,881 shares of company stock worth $4,932,284. Insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HALO. GAMMA Investing LLC boosted its stake in shares of Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares during the last quarter. Fifth Third Bancorp grew its holdings in Halozyme Therapeutics by 2.4% during the 2nd quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 261 shares during the period. FCF Advisors LLC raised its position in shares of Halozyme Therapeutics by 1.9% in the 1st quarter. FCF Advisors LLC now owns 21,164 shares of the biopharmaceutical company’s stock worth $861,000 after acquiring an additional 391 shares in the last quarter. Private Advisor Group LLC lifted its stake in shares of Halozyme Therapeutics by 1.8% in the 2nd quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after purchasing an additional 412 shares during the period. Finally, Retirement Systems of Alabama boosted its position in shares of Halozyme Therapeutics by 0.3% during the 1st quarter. Retirement Systems of Alabama now owns 165,881 shares of the biopharmaceutical company’s stock valued at $6,748,000 after purchasing an additional 436 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Further Reading